MigVax is developing an oral COVID-19 sub-unit vaccine.
The MigVax approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx.
This method, based on the IBV vaccine, generates three kinds of immunological response:
mucosal immunity- IgA
The MigVax vaccine is based on a vaccine developed for Infectious Bronchitis Virus which is a coronavirus that infects chickens.